生物识别筛选与未来雇主医疗成本：了解是否值得？
Biometric Screening and Future Employer Medical Costs: Is It Worth It to Know?
机构信息
Kalispell Regional Healthcare, The Summit Medical Fitness Center, Kalispell (Dr Vanichkachorn, Dr Roy, Mr Opel); Independent Statistician Contractor, Whitefish (Ms Marchese), Montana.
出版信息
J Occup Environ Med. 2017 Dec;59(12):1202-1210. doi: 10.1097/JOM.0000000000001188.
OBJECTIVE
To study the relationship between a biometric wellness data and future/actual medical costs.
METHODS
A relationship between total cholesterol to high density lipoprotein ratio, blood pressure, and blood glucose and medical costs, based on analysis of claims data, was explored in 1834 employees that had both wellness program biometric and claims data in 2016.
RESULT
Increased total cholesterol to HDL ratio is strongly associated with increased average costs (P < 0.01). Similarly, an increased glucose level is strongly associated with increased average costs (P = 0.001). There was no evidence of a relationship between elevated blood pressure and higher costs.
CONCLUSIONS
By investing in an employer-sponsored biometric screening of full cholesterol and glucose profiles, medium-sized employers can identify high-risk employees who are expected to incur significantly higher healthcare costs, as compared with low-risk level employees, and improve treatment outcomes.
目的
研究生物特征健康数据与未来/实际医疗成本之间的关系。
方法
通过对 2016 年的索赔数据进行分析，研究了总胆固醇与高密度脂蛋白比值、血压和血糖与医疗成本之间的关系，该研究纳入了 1834 名既有健康计划生物特征数据又有索赔数据的员工。
结果
总胆固醇与高密度脂蛋白比值升高与平均成本增加呈强相关（P<0.01）。同样，血糖水平升高与平均成本增加呈强相关（P=0.001）。高血压与更高成本之间没有关系的证据。
结论
通过投资于雇主赞助的全面胆固醇和葡萄糖检测，中型雇主可以识别出预计将比低风险水平员工产生更高医疗成本的高风险员工，并改善治疗结果。
Zotero 插件